Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Metastatic Breast Cancer|Mutation
Interventions: DRUG: Everolimus|DRUG: Investigator's Choice of Chemotherapy
Sponsor: Fudan University